Findings from ANRS 119, the Interstart trial, show that it may be possible to defer antiretroviral treatment for nearly two years by using a limited number of short courses of interleukin-2 to keep CD4 cell counts above the recommended threshold for antiretroviral treatment initiation, Jean-Michel Molina of the University of Paris reported at the XVII International AIDS Conference in Mexico City. http://www.aidsmap.org/en/news/DF6686F9-37F2-448D-8EC8-688EB007FBB5.asp